CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced Devyn Smith,...
Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the annual Cell & Gene Meeting on the Med. The congress will be held April 12-14 in Barcelona, Spain and livestreamed globally. nnOrganized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a two-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers. nnThe following are specific details regarding Arbor Biotechnologies’ presentation at the conference: nnnEvent: 2023 Cell & Gene Meeting on the Med nDate: Wednesday, April 12th nTime: 5:45AM ET / 11:45 AM CET nLocation: Hotel Arts Barcelona nMarina 19-21 nBarcelona, 08005 Spain nVirtual attendance is available which includes a livestream of Arbor Biotechnologies’ presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemed.com/ for full information including registration. nnComplimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Stephen Majors at smajors@alliancerm.org.
CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies (Arbor) today announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated (Vertex) will receive rights to Arbor’s novel precision editing technology for up to three diseases.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief...
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September.
CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Lee Ann Marchionna, MBA, to the newly created role of Chief People Officer. Ms. Marchionna joins Arbor with more than 25 years of experience in Human Resources, having led organizational effectiveness initiatives as well as establishing talent, culture, and engagement practices for both public and private life sciences companies.
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its...
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced upcoming...